Sarah Khan, MD
Endocrinology, Diabetes & Metabolism · Pompton Plains, NJNPI 1093794448
Payments from drug & device makers
Across 270 payments — averaging $18.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$477
- Novo Nordisk$473
- Corcept Therapeutics$440
- Sanofi-aventis U.S. LLC$411
- Medtronic$354
- Abbott$273
- plus $2K from 29 others
What the payments were for
- Food & beverage$4,74797%
- Education$431%
- Gifts$591%
- Other$601%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 32 | $477 |
| Novo Nordisk | 30 | $473 |
| Corcept Therapeutics | 23 | $440 |
| Sanofi-aventis U.S. LLC | 27 | $411 |
| Medtronic(2 entities) | 15 | $354 |
| Abbott | 13 | $273 |
| Xeris Pharmaceuticals, Inc. | 7 | $221 |
| Bayer | 11 | $207 |
| Amgen(2 entities) | 12 | $183 |
| Boehringer Ingelheim | 11 | $180 |
| Insulet Corporation | 9 | $177 |
| AstraZeneca(2 entities) | 9 | $155 |
| Alnylam Pharmaceuticals Inc. | 1 | $140 |
| AbbVie | 9 | $137 |
| Mannkind Corporation | 4 | $133 |
| Merck | 9 | $121 |
| Tandem Diabetes Care, Inc. | 4 | $110 |
| Amneal Pharmaceuticals LLC | 7 | $108 |
| Recordati_rare_diseases_inc. | 4 | $72 |
| Cequr Corporation | 3 | $55 |
| Ascendis Pharma Endocrinology Inc | 3 | $54 |
| Neurocrine Biosciences, Inc. | 3 | $53 |
| Amarin Pharma, Inc. | 4 | $51 |
| Eisai Inc. | 3 | $48 |
| Johnson & Johnson(2 entities) | 3 | $44 |
| IBSA Pharma Inc. | 3 | $43 |
| Ultragenyx Pharmaceutical Inc. | 2 | $35 |
| Althera Pharmaceuticals LLC | 2 | $27 |
| Dexcom, Inc. | 1 | $27 |
| Soleno Therapeutics, Inc. | 1 | $25 |
| Madrigal Pharmaceuticals | 1 | $19 |
| Braintree Laboratories, Inc. | 1 | $16 |
| Aucta Pharmaceuticals, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Shire North American Group Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GVOKE HYPOPEN$118
How this compares
$4,909 in reported general payments places this provider in the 65th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
See all endocrinology, diabetes & metabolism providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 394 | $507,109 |
| MounjaroTirzepatide | 93 | $165,201 |
| TrulicityDulaglutide | 89 | $121,573 |
| JardianceEmpagliflozin | 92 | $104,421 |
| Tresiba Flextouch U-200Insulin Degludec | 89 | $93,039 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 128 | $87,622 |
| Humalog Kwikpen U-200Insulin Lispro | 68 | $70,674 |
| ForteoTeriparatide | 13 | $56,057 |
| JanuviaSitagliptin Phosphate | 46 | $53,445 |
| TradjentaLinagliptin | 38 | $48,169 |
| FarxigaDapagliflozin Propanediol | 38 | $46,548 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $44,596 |
| Tresiba Flextouch U-100Insulin Degludec | 25 | $37,885 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 43 | $30,853 |
| ProliaDenosumab | 12 | $21,270 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $473 | $507,109394 claims |
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog | $477 | $345,803218 claims |
| Boehringer IngelheimJardiance, Tradjenta | $180 | $152,590130 claims |
| MerckJanuvia | $121 | $53,44546 claims |
| AstraZenecaFarxiga | $155 | $46,54838 claims |
| AmgenProlia | $183 | $21,27012 claims |
| Johnson & JohnsonInvokana | $44 | $12,95216 claims |
| AbbVieSynthroid | $137 | $12,635139 claims |
| Sanofi-aventis U.S. LLCLantus | $411 | $5,23525 claims |
| IBSA Pharma Inc.Tirosint | $43 | $4,49215 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $108 | $3,784331 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $13 | $3,68911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
Other endocrinology, diabetes & metabolism in Pompton Plains
- Barry GertzRahway$903K
- Nawras MakhsidaRandolph$882K
- Marc SandbergFlemington$567K
- Joanne WaldstreicherNew Brunswick$441K
- Gregory BaroneCherry Hill$433K
- Taher ModarressiPennington$414K
- Navtika DesaiHillsborough$408K
- Atara SchultzTeaneck$357K
- Anthony CannonTurnersville$296K
- Sunil AsnaniBrick$295K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.